The era solidifies stem cells as engineering platforms for regeneration, modeling, and therapeutic delivery, with emphasis on scalable cell sources and controlled differentiation. A dominant pattern is the demonstration that somatic cells can be reprogrammed to pluripotency in vitro, enabling patient-specific models and foreshadowing the rise of induced pluripotent stem cell technology. Simultaneously, genome editing and targeted cell delivery expand the toolkit for precise modification and functional assessment, while mesenchymal stem cells and neuronally differentiated derivatives illustrate early paths to cell-based therapies.